| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2013-04-22 | Royal DSM (The Netherlands) DecImmune Therapeutics (USA - MA) | undisclosed monoclonal antibody program | reduction of tissue damage and improvement of ventricular function associated with myocardial infarction | development |
Cardiovascular diseases | Development agreement |
| 2013-04-22 | Evotec (Germany) Genentech, a member of Roche group (USA - Switzerland) | undisclosed | undisclosed | R&D |
undisclosed | R&D agreement |
| 2013-04-22 | Horizon Discovery (UK) AstraZeneca (UK) | kinase target programme HD-001 | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-04-18 | Cell Therapy Catapult (UK) Loughborough University (UK) | cell therapy products | manufacturing |
Regenerative medicine | Production agreement | |
| 2013-04-18 | MolMed (Italy) Zambon (Italy) | investigational cell therapy product TK | manufacturing |
Cancer - Oncology | Production agreement | |
| 2013-04-17 | Boehringer Ingelheim (Germany) Argenta (Galapagos subsidiary – UK Belgium) | respiratory drug discovery services | undisclosed | R&D |
Respiratory diseases | R&D agreement |
| 2013-04-16 | Santaris Pharma (Denmark) BMS (USA - NY) | RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform | undisclosed | R&D |
undisclosed | R&D agreement |
| 2013-04-16 | Stada (Germany) Humatrix (Germany) | DNA tests for tamoxifen, statins and clopidogrel | distribution |
Diagnostic - Cancer - Oncology - Cardiovascular diseases | Distribution agreement | |
| 2013-04-15 | Roche (Switzerland) Ascletis (China) | danoprevir | chronic hepatitis C | development |
Infectious diseases | Development agreement |
| 2013-04-15 | AstraZeneca (UK) Oxford Cancer Biomarkers (UK) | biomarkers for an undisclosed AstraZeneca cancer drug | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-04-12 | ATMI (USA) Disposable Labs (France) | all-single-use fill/finish platform | commercialisation |
Technology - Services | Commercialisation agreement | |
| 2013-04-10 | Ipsen (France) Peptidream (Japan) | therapeutic peptides | undisclosed | R&D |
Hormonal diseases - Endocrine diseases | R&D agreement |
| 2013-04-10 | Debiopharm Group (Switzerland) Shasun Pharmaceuticals (India) | Huperzine-A | Alzheimer's disease | licensing |
Neurodegenerative diseases | Licensing agreement |
| 2013-04-10 | Bayer (Germany) German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) (Germany) | novel cancer immunotherapies | R&D |
Cancer - Oncology | R&D agreement | |
| 2013-04-10 | Sanofi (France) Pieris (Germany) | multispecific Anticalin program | R&D |
R&D agreement | ||
| 2013-04-10 | Cell Therapy Catapult (UK) the UK Stem Cell Foundation (UK) | cell therapy | R&D |
Regenerative medicine - Ophtalmological diseases - Cardiovascular diseases - Hepatic diseases - Cancer - Oncology | R&D agreement | |
| 2013-04-09 | Proteros (Germany) Priaxon (Germany) | lead compounds for high value protein-protein interaction (PPI) drug targets | R&D |
R&D agreement | ||
| 2013-04-09 | NovAliX (France) Inventiva (France) | clinical candidates targeting nuclear receptors | research - development | Research agreement | ||
| 2013-04-09 | Eddingpharm (China) GSK China | Tykerb® (lapatinib) | advanced or metastatic breast cancer | commercialisation |
Cancer - Oncology | Collaboration agreement |
| 2013-04-08 | Theratechnologies (Canada) Ferrer Internacional (Spain) | tesamorelin | excess abdominal fat in HIV-infected patients with lipodystrophy | distribution |
Metabolic diseases - Infectious diseases | Licensing agreement |
